Welcome, and thank you for visiting the website of ELBIO Inc.

ELBIO Inc is an advanced biotechnology company dedicated to developing next-generation siRNA-based gene nano-anticancer therapeutics to open new possibilities for the treatment of refractory cancers.

Cancer remains one of the leading causes of death worldwide, and refractory cancers such as pancreatic cancer and brain cancer still have significant limitations with current treatment approaches. To address these unmet medical needs, ELBIO Inc is committed to developing innovative gene therapy technologies with the goal of achieving fundamental cancer treatment.

Based on our proprietary osmotic polymer-based gene delivery platform technology, we are developing next-generation siRNA nano-anticancer therapeutics capable of simultaneously targeting both cancer cells and cancer stem cells. Through this approach, we aim to overcome the low therapeutic efficacy, side effects, and drug resistance associated with conventional anticancer therapies, while realizing safer and more effective precision cancer treatment.

Driven by continuous research, innovation, and a pioneering spirit, ELBIO Inc strives to provide new hope to patients and their families and to contribute to the advancement of the global biopharmaceutical industry.

We sincerely appreciate your continued interest and support.

Thank you.